High-Grade Neuroendocrine Neoplasms
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: 31 January 2025 | Viewed by 1116
Special Issue Editor
Special Issue Information
Dear Colleagues,
High-grade neuroendocrine neoplasms (NENs) are an increasingly encountered entity among providers who care for patients with NENs in general. High-grade NENs can either be well-differentiated grade 3 neuroendocrine tumors (G3 NETs) or poorly differentiated neuroendocrine carcinomas (NECs). Until relatively recently, G3 NETs were not recognized as a separate entity.
The current classification of high-grade (grade 3, G3) NENs clearly separates G3 NETs from NECs, but the distinction can be challenging for pathologists. Their natural history, response to therapy, and prognosis are very different, and only a few prospective trials have specifically addressed each entity within the G3 NEN spectrum.
This Special Issue aims to provide up-to-date information on the increasingly complex management of patients with G3 NENs. The role of the pathologist and the increasing role of molecular analysis will be discussed, and these discussions will be followed by reviews concerning the management of G3 NENs. As the management of G3 NETs differs substantially from the management of NECs, it will be discussed in a separate section. The current status of systemic therapy for NECs and the expanding roles of molecular testing and targeted therapy will be covered in detail.
We encourage all contributors, ideally a diverse group of contributors from different regions of the world, to add their voice and perspectives to the current state of the biology and management of patients with high-grade NENs.
Dr. Thorvardur Halfdanarson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroendocrine tumor
- neuroendocrine carcinoma
- small cell carcinoma
- large cell carcinoma
- chemotherapy
- immunotherapy
- peptide receptor radionuclide therapy
- alpha particle therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
